In Q1 2023, Perceptive Advisors held 66 positions worth $2.7B. They initiated 66 new positions. Their largest holding was FOLD ($306.8M).
Frequently asked questions
What stocks did Perceptive Advisors own in Q1 2023?
Perceptive Advisors held 66 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include FOLD, AMLX, CERE, MDGL, RXDX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q1 2023?
Perceptive Advisors's tracked biotech portfolio was worth $2.7B across 66 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q1 2023?
Perceptive Advisors initiated 66 new positions in Q1 2023, including FOLD, AMLX, CERE, MDGL, RXDX and 61 more. They also increased 0 existing positions.
What did Perceptive Advisors sell in Q1 2023?
Perceptive Advisors did not fully exit any positions in Q1 2023.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisors portfolio →